Free for academic non-profit institutions. Other users need a Commercial license
The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells. The encoded protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Finally, this protein binds to the product of the APC gene, which is mutated in adenomatous polyposis of the colon. Mutations in this gene are a cause of colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2016]
CTNNB1 (Catenin Beta 1) is a Protein Coding gene. Diseases associated with CTNNB1 include Pilomatrixoma and Neurodevelopmental Disorder With Spastic Diplegia And Visual Defects. Among its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and Regulation of Wnt-mediated beta catenin signaling and target gene transcription. Gene Ontology (GO) annotations related to this gene include DNA-binding transcription factor activity and binding. An important paralog of this gene is JUP.
beta-catenin protein is an integral part of the canonical Wnt signaling pathway. Wnt binding to Frizzled (Fz) receptors and LRP co-receptors activates Dishevelled (Dsh) proteins; these in turn inhibit the destruction complex responsible for degrading beta-catenin, which includes GSK-3.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001085 | RNA polymerase II transcription factor binding | IDA,IPI | 18936100 |
GO:0001102 | RNA polymerase II activating transcription factor binding | IPI | 19443654 |
GO:0003682 | chromatin binding | ISS | -- |
GO:0003700 | DNA-binding transcription factor activity | IEA | -- |
GO:0003713 | transcription coactivator activity | IBA,IMP | 12949260 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000922 | spindle pole | IEA | -- |
GO:0005623 | cell | IEA | -- |
GO:0005634 | nucleus | IEA,IDA | 9707618 |
GO:0005654 | nucleoplasm | TAS | -- |
GO:0005667 | transcription factor complex | IDA | 11751639 |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | S45 mutants of beta-catenin arent phosphorylated | ||
2 | Endometrial cancer |
Signal transduction PTEN pathway
.44
|
.36
.32
|
3 | Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling | ||
4 | Apoptotic execution phase |
.31
|
|
5 | Regulation of activated PAK-2p34 by proteasome mediated degradation |
.41
|
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000122 | negative regulation of transcription by RNA polymerase II | IEA | -- |
GO:0000209 | protein polyubiquitination | IDA | 29374064 |
GO:0000578 | embryonic axis specification | IEA | -- |
GO:0000904 | cell morphogenesis involved in differentiation | IEA | -- |
GO:0001501 | skeletal system development | IEA | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Urea | Approved, Investigational | Pharma | Target | 0 | ||
Dexamethasone | Approved, Investigational, Vet_approved | Pharma | Agonist | Anti-inflammatory glucocorticoid | 2886 | |
Cyclophosphamide | Approved, Investigational | Pharma | Nitrogen mustard alkylating agent and prodrug. | 3670 | ||
Lenalidomide | Approved | Pharma | Anti-angiogenic. | 911 | ||
Thalidomide | Approved, Investigational, Withdrawn | Pharma | Immunomodulatory agent,sedative drug,angiogenesis inhibitor, TNF-alpha synthesis inhibitor, Immunomodulatory agents | 429 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
endo-IWR 1 |
|
1127442-82-3 |
|
|
Compound | Action | Cas Number |
---|---|---|
endo-IWR 1 | Wnt/beta-catenin signaling inhibitor; axin stabilizer | 1127442-82-3 |
exo-IWR 1 | Negative control for endo-IWR 1 (Cat. No. 3532) | 1127442-87-8 |
FH 535 | Inhibitor of Wnt/beta-catenin signaling | 108409-83-2 |
iCRT 14 | Inhibits beta-catenin-responsive transcription (CRT) | 677331-12-3 |
PNU 74654 | beta-catenin binder; inhibits Wnt signaling | 113906-27-7 |
Compound | Action | Cas Number |
---|---|---|
Cardiogenol C hydrochloride | 1049741-55-0 | |
Cardionogen 1 | 577696-37-8 | |
CCT 031374 hydrobromide | Inhibits TCF-dependent transcription | 1219184-91-4 |
CCT251545 | Orally bioavailable and potent WNT signaling inhibitor | 1661839-45-7 |
exo-IWR 1 | 1127442-87-8 | |
FH535 | Wnt/B-catenin inhibitor | 108409-83-2 |
ICG 001 | Wnt/β-catenin pathway inhibitor | 847591-62-2 |
iCRT 14 | CRT inhibitor | 677331-12-3 |
IDE 1 | 1160927-48-9 | |
IDE 2 | 1136466-93-7 | |
IQ 1 | 331001-62-8 | |
ISX 9 | 832115-62-5 | |
IWP 4 | 686772-17-8 | |
IWR-1-endo | Potent Wnt signaling inhibitor | 1127442-82-3 |
JW 67 | 442644-28-2 | |
Kartogenin | 4727-31-5 | |
KHS 101 hydrochloride | ||
KY 02111 | WNT signaling inhibitor | 1118807-13-8 |
LGK-974 | PORCN inhibitor,potent and specific | 1243244-14-5 |
Neurodazine | 937807-66-4 | |
PNU 74654 | 113906-27-7 | |
QS 11 | Wnt synergistic agonist | 944328-88-5 |
Salinomycin | Polyether ionophore antibiotic;anti-cancer | 53003-10-4 |
Shz 1 | 326886-05-9 | |
TCS 2210 | 1201916-31-5 | |
WAY-262611 | 1123231-07-1 | |
Windorphen | Wnt inhibitor | 19881-70-0 |
Wnt-C59 | PORCN inhibitor,highly potent and selective | 1243243-89-1 |
ExUns: | 1 | ^ | 2a | · | 2b | · | 2c | · | 2d | · | 2e | ^ | 3 | ^ | 4 | ^ | 5 | ^ | 6 | ^ | 7a | · | 7b | ^ | 8a | · | 8b | ^ | 9a | · | 9b | · | 9c | ^ | 10a | · | 10b | · | 10c | ^ | 11 | ^ | 12 | ^ | 13 | ^ | 14 | ^ | 15a | · | 15b | · |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
SP2: | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
SP3: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP4: | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
SP5: | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
SP6: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP7: | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||
SP8: | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
SP9: | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
SP10: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP11: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP12: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP13: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP14: |
ExUns: | 15c | · | 15d | ^ | 16a | · | 16b | ^ | 17a | · | 17b | ^ | 18a | · | 18b | · | 18c | · | 18d | ^ | 19 | ^ | 20 | ^ | 21a | · | 21b |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | - | ||||||||||||||||||||||||
SP2: | - | - | - | ||||||||||||||||||||||||
SP3: | - | - | - | - | |||||||||||||||||||||||
SP4: | |||||||||||||||||||||||||||
SP5: | |||||||||||||||||||||||||||
SP6: | |||||||||||||||||||||||||||
SP7: | |||||||||||||||||||||||||||
SP8: | |||||||||||||||||||||||||||
SP9: | |||||||||||||||||||||||||||
SP10: | - | ||||||||||||||||||||||||||
SP11: | |||||||||||||||||||||||||||
SP12: | - | - | |||||||||||||||||||||||||
SP13: | - | ||||||||||||||||||||||||||
SP14: |
This gene was present in the common ancestor of animals.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Oppossum (Monodelphis domestica) |
Mammalia | CTNNB1 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia |